quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:00:00·26d
PRRelease
MoonLake Immunotherapeutics logo

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MLTX· MoonLake Immunotherapeutics
Health Care
Original source

Companies

  • MLTX
    MoonLake Immunotherapeutics
    Health Care

Recent analyst ratings

  • Mar 23UpdateWolfe Research$24.00
  • Mar 19UpdateRothschild & Co Redburn$40.00
  • Jan 15UpdateGoldman$10.00
  • Jan 9UpdateBTIG Research$24.00
  • Nov 3UpdateH.C. Wainwright$30.00
  • Oct 2UpdateH.C. Wainwright-

Related

  • SEC2d
    SEC Form DEFA14A filed by MoonLake Immunotherapeutics
  • SEC2d
    SEC Form DEF 14A filed by MoonLake Immunotherapeutics
  • INSIDER7d
    SEC Form 4 filed by Bodenstedt Matthias
  • INSIDER9d
    SEC Form 4 filed by Santos Da Silva Jorge
  • INSIDER13d
    SEC Form 4 filed by Bodenstedt Matthias
  • INSIDER21d
    SEC Form 4 filed by Bvf Partners L P/Il
  • SEC21d
    Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics
  • SEC23d
    SEC Form 144 filed by MoonLake Immunotherapeutics
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022